Oppenheimer & Co. Inc. Boosts Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Oppenheimer & Co. Inc. grew its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 52.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 104,231 shares of the biotechnology company's stock after purchasing an additional 35,823 shares during the period. Oppenheimer & Co. Inc. owned about 0.23% of Capricor Therapeutics worth $1,438,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in Capricor Therapeutics by 32.6% during the 4th quarter. Bank of New York Mellon Corp now owns 84,027 shares of the biotechnology company's stock worth $1,160,000 after buying an additional 20,638 shares in the last quarter. Black Diamond Financial LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $3,833,000. New York State Common Retirement Fund grew its position in shares of Capricor Therapeutics by 625.0% during the fourth quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock worth $80,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Capricor Therapeutics by 44.4% during the fourth quarter. Rhumbline Advisers now owns 46,083 shares of the biotechnology company's stock worth $636,000 after buying an additional 14,169 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Capricor Therapeutics by 74.8% in the fourth quarter. SG Americas Securities LLC now owns 15,317 shares of the biotechnology company's stock valued at $211,000 after acquiring an additional 6,552 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on CAPR. Cantor Fitzgerald boosted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Tuesday. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $34.50.

Capricor Therapeutics Price Performance

NASDAQ CAPR traded down $1.13 on Wednesday, hitting $12.57. 1,647,153 shares of the company's stock were exchanged, compared to its average volume of 1,330,887. The firm has a market cap of $571.42 million, a price-to-earnings ratio of -11.87 and a beta of 4.08. Capricor Therapeutics Inc has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The firm's 50-day moving average price is $14.40 and its two-hundred day moving average price is $13.93.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.